What Is GLP-3? The Term Behind Triple-Agonist Drugs

Where the Term GLP-3 Came From

The name follows a pattern readers already recognize from GLP-1 drugs like Ozempic and Wegovy. Retatrutide, developed by Eli Lilly, acts on three separate hormone receptors: GLP-1, GIP, and glucagon. Tirzepatide already targets two of those, GLP-1 and GIP. Retatrutide goes one receptor further, and some coverage started calling it a "triple-G" or "GLP-3" drug as a shorthand for that extra target. For the full head-to-head numbers, see our retatrutide vs semaglutide comparison.

The label stuck in headlines partly because it is easy to say and partly because it implies a clean next step in a numbered progression. Neither the FDA nor any peer-reviewed endocrinology literature recognizes GLP-3 as an official term. Retatrutide's own trial publications and Eli Lilly's own materials describe it as a GLP-1/GIP/glucagon receptor triple agonist, never as a GLP-3 drug.

The gap between the nickname and the science matters beyond pedantry. A reader who searches "GLP-3" expecting a fourth weight-loss hormone can walk away with a wrong picture of how these drugs work. That wrong picture makes it harder to weigh real trade-offs, like side effects or trial results, against what is currently approved. Getting the terminology right is the first step toward reading trial coverage accurately.

Why There Is No GLP-2 Weight-Loss Drug Either

GLP-2, unlike GLP-3, is a real hormone. Your intestine produces it alongside GLP-1 from the same precursor protein, proglucagon. But GLP-2 does a different job entirely. It supports intestinal lining growth and nutrient absorption instead of appetite or blood sugar regulation. That is why the one FDA-approved GLP-2 drug, teduglutide, treats short bowel syndrome rather than weight or diabetes.

That distinction matters for the GLP-3 naming pattern. If drug names followed real hormone numbering, the next weight-loss hormone after GLP-1 would logically be GLP-2. It already exists, for an unrelated condition. "GLP-3" skips over that inconvenient fact and invents a number that was never assigned to any real hormone.

GLP-3 vs GLP-1 and Other Real Incretin Hormones

Only two hormones drive the receptor targets behind today's approved and late-stage weight and diabetes drugs: GLP-1 and GIP. Both are incretins, hormones released from the gut after eating that help the pancreas release insulin and slow digestion. Semaglutide (Ozempic, Wegovy) targets GLP-1 alone. Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP.

Retatrutide adds a third target, and that third target is glucagon. Glucagon is a pancreatic hormone that normally raises blood sugar, so it is not a new incretin at all. Calling that combination "GLP-3" glosses over a real mechanistic difference. Retatrutide pairs the appetite and blood-sugar-lowering signals from GLP-1 and GIP with a receptor that raises resting energy expenditure through a separate pathway.

That third pathway is the reason researchers are studying triple agonists for greater weight loss than dual agonists like tirzepatide achieve alone. Glucagon receptor activation increases how many calories the body burns at rest, largely through effects on the liver and fat tissue. The GLP-1 and GIP components offset glucagon's usual blood-sugar-raising effect and suppress appetite at the same time. On blood sugar, the three signals partly cancel each other out. On total energy balance, they add up. That trade-off is the real rationale behind a third target, and none of it requires calling the drug a hormone it is not.

Other Drugs That Sometimes Get the GLP-3 Label

Retatrutide is not the only multi-receptor candidate in development, and the loose "GLP-3" nickname sometimes gets pinned on drugs that do not even fit its own logic. Survodutide and pemvidutide, for example, are GLP-1/glucagon dual agonists, with no GIP component at all. They target two receptors, the same count as tirzepatide, just a different pair.

CagriSema is a different case again: a combination of semaglutide (a GLP-1 agonist) with cagrilintide, an amylin analog. It does not add a third incretin receptor at all. None of these drugs act on three hormone receptors the way retatrutide does, so applying the same "GLP-3" shorthand to them is doubly imprecise. A headline that calls a drug "GLP-3" without naming its actual receptor targets is the clearest sign the label is being used loosely rather than accurately.

When Will a GLP-3 Drug Be Available?

No product will ever launch under an FDA-approved "GLP-3" label. That is not a recognized drug class the agency reviews applications against. The real question readers usually mean to ask is when retatrutide itself might reach pharmacy shelves.

Retatrutide has moved through Phase 3 obesity trials. Eli Lilly has indicated it is targeting a regulatory submission and a potential approval decision in this window, though exact FDA timelines are never guaranteed and can shift. Our three-way GLP-1 drug comparison tracks how retatrutide stacks up against the two already-approved options while it waits on that decision.

Anyone tracking the drug specifically should watch Eli Lilly's own investor relations updates and clinical-trial communications. Secondhand "GLP-3 news" coverage sometimes conflates retatrutide's timeline with the other compounds described above. Most of those are years behind it in development, and each answers to its own separate regulatory timeline.